Vivimed Labs' recent board meeting saw key decisions.

The consolidated financial results for the quarter ended June 30, 2025, were approved.

While reporting a ₹5.49 Cr net loss, auditors highlighted a major concern: ₹14.98 Cr in unrecorded interest expenses could push the consolidated loss to ₹20.48 Cr.

The company also faces defaults on ₹374.82 Cr dues, with loans now NPAs.

Furthermore, the board re-appointed Mr. Santosh Varalwar as MD, and Mr. Sandeep Varalwar & Mr. Manohar Rao Varalwar as Whole-time Directors for five-year terms.

Pledging overseas assets for fundraising/debt will be put to shareholder approval.